[
  {
    "ts": null,
    "headline": "DexCom, Inc. (DXCM): A Bull Case Theory",
    "summary": "We came across a bullish thesis on DexCom, Inc. on Flyover Stocks Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $76.22 as of September 12th. DXCM’s trailing and forward P/E were 53.68 and 29.41 respectively according to Yahoo Finance. DexCom (DXCM) is a leading […]",
    "url": "https://finnhub.io/api/news?id=5b826d52ba1071d8c632ae94538e239f45f95b9f5c878fba15f7e969ffe25d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758127385,
      "headline": "DexCom, Inc. (DXCM): A Bull Case Theory",
      "id": 136790026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on DexCom, Inc. on Flyover Stocks Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $76.22 as of September 12th. DXCM’s trailing and forward P/E were 53.68 and 29.41 respectively according to Yahoo Finance. DexCom (DXCM) is a leading […]",
      "url": "https://finnhub.io/api/news?id=5b826d52ba1071d8c632ae94538e239f45f95b9f5c878fba15f7e969ffe25d36"
    }
  },
  {
    "ts": null,
    "headline": "Does DexCom's Interim Leadership Shift Alter the Strategic Outlook for DXCM?",
    "summary": "DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as interim chairman. At the European Association for the Study of Diabetes Annual Meeting on September 15, DexCom presented new clinical data highlighting the impact and cost-effectiveness of its glucose monitoring technology for diverse diabetes populations. We'll consider how the interim leadership...",
    "url": "https://finnhub.io/api/news?id=86b5c2d70ee51a22acbb314d0028a30cf653b86b58f5793b3d11208b69105fdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758114828,
      "headline": "Does DexCom's Interim Leadership Shift Alter the Strategic Outlook for DXCM?",
      "id": 136789172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as interim chairman. At the European Association for the Study of Diabetes Annual Meeting on September 15, DexCom presented new clinical data highlighting the impact and cost-effectiveness of its glucose monitoring technology for diverse diabetes populations. We'll consider how the interim leadership...",
      "url": "https://finnhub.io/api/news?id=86b5c2d70ee51a22acbb314d0028a30cf653b86b58f5793b3d11208b69105fdd"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock Worth Your Attention and 2 We Brush Off",
    "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 16.4%.",
    "url": "https://finnhub.io/api/news?id=a73b7edfa77c160a6a458be61135a1a8b02da9a1207645868c9d31c61c1dd637",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758087491,
      "headline": "1 Healthcare Stock Worth Your Attention and 2 We Brush Off",
      "id": 136787763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 16.4%.",
      "url": "https://finnhub.io/api/news?id=a73b7edfa77c160a6a458be61135a1a8b02da9a1207645868c9d31c61c1dd637"
    }
  }
]